NewsSource: EClinCloud

EClinCloud Invites You to the 2025 CMAC Annual Conference to Discuss AI + eCOA Enabling Clinical Trials

1 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.


From March 18 to 20, EClinCloud will appear at the 2025 CMAC Annual Conference, and we invite colleagues across the pharmaceutical industry to gather and discuss how eCOA enables clinical trials and frontier applications of AI technology.





Article image

Presentations and Roundtable Discussions


Article image

Su Quanyu

Co-Founder and Chief Commercial Officer, EClinCloud


Sub-forum:

Electronic Clinical Outcome Assessment (eCOA): DCT Elements with Vast Potential and Practical Implementation


Time and Venue: 

March 19, 9:20–9:40, 2nd Floor, Room A211

Keynote Presentation:

"Crossing Boundaries, Addressing Core Needs: eCOA Enabling Clinical Trials"


Time and Venue:

March 19, 11:15–12:00, 2nd Floor, Room A211

Roundtable Discussion:

"Challenges and Strategies in the Localized Application of eCOA/ePRO"


Booth Activities: B27





Check in at the EClinCloud booth on-site to receive a gift


Article image




Conference Information


8973752cabfed0ce1b586ed0687b387.jpg

Image source: CMAC


Conference Dates: March 18–20 

Venue: Suzhou International Expo Center

Conference Agenda:


Article image

Scan the QR code to view the agenda





About EClinCloud

EClinCloud is a leading AI company in the clinical research industry, building an AI-driven integrated intelligent clinical cloud platform and endpoint assessment technologies to provide global pharmaceutical companies and research institutions with technology products including eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as scale management, linguistic validation, rater training, and data quality analysis services, creating efficient and precise digital solutions. Leveraging AI predictive models and an intelligent data platform, EClinCloud dynamically evaluates and helps improve the success rate of drug clinical trials, helping shorten drug and medical device R&D cycles for the benefit of patients.  







Article image

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.